PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the pagework Resident Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449A/PT	-0		Complete if Known		
"	oonidio for form 1440/VI			Application Number	10/644,775	
l Ir	NFORMATIO	N DISC	CLOSURE	Filing Date	08/21/2003	
5	STATEMENT	BY AP	PLICANT	First Named Inventor	Tennenbaum	
`	, , , , , <u> </u>	,		Art Unit	1647	
	(use as many s	sheets as nec	ressary)	Examiner Name	Marianne P. Allen	
Sheet	1	of	2	Attorney Docket Number	HEALOR-202	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant		
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear		
/MA/	1	6,737,241	05-18-2004	Nolan et al.			
8	2	4,940,660	07-10-1990	Hirai			
11/	3	6,319,907	11-20-2001	Ferguson			
₩	4	6,582,713	06-24-2003	Newell, et al.			

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	П
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			Passages or Relevant Figures Appear	T ⁶
/MA/	5	WO 1990/011071 A1	10-04-1990	Dana Farber Cancer Institute		
	6	WO 1993/025660 A1	12-23-1993	Brigham and Women's Hosp.		
	7	WO 2002/072092 A1	09-19-2002	University of Kentucky		
	8	WO 2002/09639	07-07-2002	Tennenbaum, et al.		L
1 /	9	WO 2002/017980 A2	03-07-2002	Modex Therapeutics		
V	10	WO 2005/007072	01-27-2005	Tennenbaum, et al.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(symposium, catalog, etc), date, page(symposium, catalog, etc), date, page(symposium, catalog, etc), date, page(symposium, catalog, etc), date, page(symposium, catalog, etc), date, etc),			
/MA/	11	Al, et al. "The experimental study of bone marrow mesenchymal stem cells on the repair of skin wound combined with local radiation injury", <i>Zhonhghua Yi Xue Za Zhi</i> , 82(23), (2002), pp. 1632-36; Pubmed Abstract PMID 12667374		
	12	ALESSENKO, et al., Biochem. Biophys, Commun., 182, (1992), pp. 1333-1339		
	13	BAJOU, et al., Nat. Med., 4 (1998), pp. 923-928		
	14	BANDYOPADHYAY, et al., Biochem. J., 337 (1999), pp. 461-470		
900	15	BENES, et al., Cell, 121 (2005), pp. 271-280		
000000000	16	BRAIMAN, "Protein Kinase Co Mediates Insulin-Induced Glucose Transport in Primary Cultures of Rat Skeletal Muscle", <i>Endocrin.</i> , 13(12), pp. 2002-2012		
8	17	CHIDA, et al., Mol. Cell Biol. 14 (1994), pp. 3782-90		
8	18	DENNING, et al., Cell Growth Differ., 6 (1995), pp. 149-157		
8	19	DLUGOSZ and YUSPA, j. Cell. Biol., 120 (1993), pp. 217-225		
11/	20	FORMISANO, et al., J. Biol, Chem., 273 (1998), pp. 12197-13202		
$\neg \mathbb{V}$	21	GSHWENDT, Eur. J. Biochem., 259 (1999), pp. 555-564		

Examiner Signature	/Marianne Allen/	Date Considered	12/17/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	estitute for form 1449A/PTO			Complete if Known		
				Application Number	10/644,775	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	08/21/2003	
S	STATEMENT I	BY A	APPLICANT	First Named Inventor	Tennenbaum	
				Art Unit	1647	
	(use as many sh	eets as	necessary)	Examiner Name	Marianne P. Allen	
Sheet	2	of	2	Attorney Docket Number	HEALOR-202	

/MA/	22	HOFMANN, The FASEB J., 11 (1997), pp. 649-669	
	23	MADIBALLY, et al. "Influence of insulin therapy on burn wound healing in rats", J. Surg. Res.,	
8		109 (2003), pp. 92-100.	
8	24	MISCHAK, et al., J. Biol. Chem., 268 (1993), pp. 20110-20115	
0000	25	MISCHAK, et al. "Overexpression of Protein Kinase C-δ and –ε in NIH 3T3 Cells Induces	
8		Opposite Effects []", J. Biol. Chem., 268(9), (1993), pp. 6090-96	
8	26	MOONEY, et al. "Tumor necrosis factor and wound healing", Annals of Surgery, 211 (2),	
88		(1990) pp. 124-129	
XX	27	OSADA, et al., <i>J. Biol. Chem.</i> , 265 (1990), pp. 22434-22440	
0000	28	PELLEGRINI, et al. "Cultivation of human keratinocyte stem, cells: current and future clinical	
88		applications", Med. Biol. Eng. Comp. 36(6), (1998), pp. 778-790	
999	29	PERLETTI, et al. "Protein Kinase Cε is oncogenic in colon epithelial cell s by interaction with	
9		the ras signal transduction pathway", Oncogene 16 (1998), pp. 3345-48	
8	30	REYNOLDS, et al., Br. J. Dermatol., 133(2), (1995), pp.157-167	
8	31	RING, et al. "Systematically and topically administered leptin both accelerate wound healing in	
		diabetic ob/ob mice", Endocrin., 141(1), (2000), pp. 446-449	
8	32	SERVOLD, et al., "Growth factor impact on wound healing", Clinics in Pod. Med. Surg., 8(4),	
		(1991), pp. 937-953	
	33	SHEN, et al., "Protein Kinase C activation: a divergence point in the signaling of insulin and	
		insulin like growth factor-1 induced proliferation of skin keratinocytes", Bar Illan Univ., Ramat	
		Gan, Israel (ABSTRACT)	
	34	SOLTOFF and TOKER, J. Biol. Chem., 270 (1995), pp. 13490-13495	
8888	35	SPRAVCHIKOV, et al., "The interactive effects of hyperglycemia, insulin and IGF-1 in murine	
8888	1	skin cells – an IR-null mouse model", Dept. of Pathol., Sackler School of Medicine, Tel Aviv	
<u> </u>		Univ., Israel (ABSTRACT)	
 	36	SUN, et al., Cancer Res., 52 (1992), pp. 4254-4260	
<u> </u>	37	TENNENBAUM, et al., Cell Growth Differ., 7 (1996), pp. 615-628	
⊢.	38	WANG, et al., J. Biol. Chem., 274 (1999), pp. 37233-37239	
	39	WERTHEIMER, et al., "The effects of insulin signaling on skin proliferation and differentiation –	
.	1	lessons from the IR- and IRS1 Null Models", Dept. of Pathol., Sackler School of Medicine, Tel	
	10	Aviv Univ., Israel (ABSTRACT)	
N/	40	WERTHEIMER, et al., J. Invest. Dermatol., 2000	
-	41	YUSPA, Cancer Res., 54 (1994), pp. 1178-1189	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Marianne Allen/	Date Considered	12/17/2007
Signature		Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.